Patients with 
Psoriasis
GENERALIZED PUSTULAR PSORIASIS, ERYTHRODERMIC PSORIASIS, PSORIASIS
All patients with GPP achieved the primary end point of clinical response at week 16 with risankizumab treatment, regardless of dose (Table Efficacy of risankizumab in Japanese patients with GPP or EPAbbreviations: CI, confidence interval; DLQI 0/1, Dermatology Life Quality Index of 0 or 1 (no effect); PASI 90; ≥90% reduction from baseline in Psoriasis Area and Severity Index.Three patients with generalized pustular psoriasis (GPP) discontinued after week 16, one discontinued after week 52, and one discontinued after week 124.Two patients with erythrodermic psoriasis (EP) discontinued after week 52.Clinical response is defined as the proportion of patients achieving GPP clinical response (“slightly improved” in the overall improvement rating from baseline according to the Japanese Dermatological Association [JDA] total score) for patients with GPP or the proportion of patients achieving EP clinical response (“minimally improved” in the Clinical Global Impression‐Global Improvement scale) for patients with EP.Japanese Dermatological Association (JDA) total score over time in patients with generalized pustular psoriasis (GPP). (a) Mean change from baseline by visit. (b) JDA total score for individual patients; each colored line represents one patient.